Codexis Announces Proposed Public Offering of Common Stock
Rhea-AI Summary
Codexis (Nasdaq: CDXS) has commenced an underwritten public offering of its common stock, with all shares to be sold by the company. Codexis also expects to grant underwriters a 30-day option to purchase up to an additional 15% of the offered shares on the same terms.
The size and terms of the offering remain subject to market and other conditions, and completion is not assured. According to Codexis, net proceeds are intended for working capital and general corporate purposes, including research, development and business activities. Piper Sandler and Cantor are joint bookrunning managers, with Craig-Hallum as co-manager. The offering uses an SEC registration statement declared effective on May 14, 2024 and will be made via prospectus and prospectus supplement.
Positive
- Equity financing underway via underwritten public offering to raise cash for working capital and corporate purposes
- Use of proceeds targeted to research, development and business activities, supporting Codexis’ growth plans
- Effective SEC shelf registration declared effective May 14, 2024 enables timely access to capital markets
- Reputable underwriters Piper Sandler and Cantor as joint bookrunning managers, with Craig-Hallum as co-manager
Negative
- Common stock issuance implies shareholder dilution as all offered shares are newly issued by Codexis
- Offering not guaranteed, with completion, size and terms subject to market and other conditions and no assurance of closing
News Explained
Existing holders face potential ownership dilution, but the proposed offering’s size and cash proceeds remain undisclosed.
Codexis has commenced, but not completed, a company-only common-stock offering; if shares are issued, total shares rise and existing holders’ percentage ownership falls.
The release does not disclose the offering’s size or terms, so the cash proceeds and resulting dilution cannot yet be quantified. In an underwritten offering, an investment bank buys the securities from the issuer for resale, and underwriting fees reduce net proceeds below the gross amount.
As of
The company says a preliminary prospectus supplement will be filed with the SEC; that filing is the named milestone for additional offering terms.
Sources and calculations
- Codexis proposed public offering announcement (2026-07-23)
- Dilution definition (undated)
- Underwritten offering definition (undated)
- Codexis first-quarter 2026 fundamentals (2026Q1)
- Cash and equivalents vs quarterly operating cash outflow, in days of cash use $36,571,000 / ($13,150,000 / 90) = [object Object]
Market reaction: CDXS -20.10% on public offering
Following this news, CDXS has declined 20.10%, reflecting a significant negative market reaction. Our momentum scanner has triggered 6 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $1.59. This price movement has removed approximately $46M from the company's valuation.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 20 | RNA manufacturing update | Positive | +1.6% | Codexis highlighted RNA manufacturing advances and sustainability improvements at TIDES USA. |
| May 07 | 1Q26 earnings report | Positive | +10.5% | Codexis reported first-quarter revenue, reiterated guidance, and disclosed cash funding operations through 2027. |
| Apr 29 | Conference presentation notice | Neutral | -0.3% | Codexis announced presentations on RNA manufacturing, process performance, and sustainability at TIDES USA. |
| Apr 23 | Earnings date announcement | Neutral | +2.0% | Codexis scheduled its first-quarter results release and investor conference call for May 7. |
| Mar 11 | 4Q25 earnings report | Positive | +34.6% | Codexis reported fourth-quarter results, a Merck technology agreement, and 2026 revenue guidance. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Positive operating and earnings updates historically aligned with gains, while scheduling and conference-related news produced mixed reactions.
Key Terms
underwritten public offering financial
registration statement regulatory
prospectus supplement regulatory
net proceeds financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., July 23, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex oligonucleotide therapeutics, today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares to be sold in the offering will be offered by Codexis. In addition, Codexis intends to grant to the underwriters a 30-day option to purchase up to an additional
Codexis intends to use the net proceeds from the offering to fund working capital and other general corporate purposes, including research, development and business activities.
Piper Sandler and Cantor are acting as joint bookrunning managers for the offering. Craig-Hallum is acting as co-manager.
A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission (SEC) and was declared effective on May 14, 2024. The offering is being made only by means of a written prospectus and prospectus supplement that will form a part of the registration statement. A preliminary prospectus supplement relating to the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Copies of the prospectus and the preliminary prospectus supplement relating to the offering may also be obtained, when available, by contacting Piper Sandler & Co., Attention: Prospectus Department, 350 North 5th Street, Suite 1000, Minneapolis, MN 55401, by telephone at (800) 747-3924, or via email at prospectus@psc.com; or Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, 6th floor, New York, NY 10022 or by email at prospectus@cantor.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful, prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Codexis, Inc.
Codexis® is a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, leveraging its proprietary CodeEvolver® technology to discover, develop and enhance novel, high-performance enzymes. Codexis enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route.
Forward-Looking Statements
To the extent that statements contained in this press release are not descriptions of historical facts regarding Codexis, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor of the Private Securities Litigation Reform Act of 1995, including Codexis’ expected use of the proceeds of the public offering. Such forward-looking statements involve substantial risks and uncertainties that could cause Codexis’ future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties related to market conditions and the completion of the public offering on the anticipated terms or at all. Codexis undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Codexis’ business in general, please refer to Codexis’ prospectus supplement to be filed with the SEC, including the documents incorporated by reference therein, which include Codexis’ Quarterly Report on Form 10-Q filed with the SEC on May 7, 2026, and Codexis’ other periodic reports filed with the SEC.
Investor Relations Contact:
Georgia Erbez
(650) 421-8100
ir@codexis.com
